

Company Overview

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high quality purified proteins - notably cytokines and growth factors, antibodies, immunoassays, as well as biologically active small molecule compounds - which are sold to biomedical researchers and clinical research laboratories; these operations constitute the core Biotech Division, headquartered in Minneapolis, Minnesota.

The Protein Platform Division manufactures innovative protein analysis tools under the ProteinSimple brand name that greatly automate western blotting and immunoassay practices. The Diagnostics Division manufactures FDA-regulated controls, calibrators, blood gas and clinical chemistry controls for OEM customer and clinical customers. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses.

With thousands of products in its portfolio, Bio-Techne generated approximately \$563 million in net sales in fiscal 2017 and has approximately 1,800 employees worldwide.

Bio-Techne To Present At The Jefferies 2018 Healthcare Conference

May 24 2018, 10:00 AM EDT

Bio-Techne To Present At The UBS Global Healthcare Conference

May 10 2018, 10:00 AM EDT

Bio-Techne Declares Dividend

May 2 2018, 7:00 AM EDT

Stock Overview

Symbol	TECH
Exchange	NASDAQ
Market Cap	5.59b
Last Price	\$148.82
52-Week	\$109.120002 - \$154.559997

05/25/2018 04:00 PM EDT

Investor Relations

David Clair
T: 646-277-1266
ir@bio-techne.com

Management Team

Charles (Chuck) Kummeth

President and Chief Executive Officer

Jim Hippel

Chief Financial Officer

David Eansor

Senior VP, Biotech Division

Brenda Furlow

Senior VP and General Counsel

Robert Gavin

Senior VP, Protein Platforms Division

Kevin Gould

Senior VP, Diagnostics Division

Kim Kelderman

President, Diagnostics and Genomics

Bio-Techne Corporation

614 McKinley Place NE
Minneapolis, MN 55413

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.